Shanghai Junshi Biosciences Co., Ltd. — Capital/Financing Update 2021

Jun 9, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [90 x 33] intentionally omitted <==

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People’s Republic of China with limited liability)

(Stock code: 1877)

APPROVAL FROM THE CSRC FOR THE ISSUANCE OF NEW H SHARES

References are made to the circular of Shanghai Junshi Biosciences Co., Ltd. (上海君實生物醫藥 科技股份有限公司) (the “ Company ”) dated 22 October 2020 and the poll results announcement of the Company dated 16 November 2020 in respect of, among other things, the proposed grant to the board (the “ Board ”) of directors (the “ Directors ”) of the Company of an unconditional general mandate to, subject to market conditions and the needs of the Company, separately or concurrently issue, allot and deal with A shares of the Company (“ A Shares ”) and/or H shares of the Company (“ H Shares ”) or securities convertible into such shares, options, warrants or similar rights to subscribe for any A Shares and/or H Shares not exceeding each of 20% of the A Shares or H Shares in issue as at the date of passing the resolution. The resolution was passed at the 2020 third extraordinary general meeting of the Company held on 16 November 2020 (the “ Date of Resolution* ”). As at the Date of Resolution, the Company had an aggregate of 872,496,000 shares in issue, comprising 689,749,500 A Shares and 182,746,500 H Shares. As such, the Board will be entitled to issue a maximum of 137,949,900 A Shares and/or 36,549,300 H Shares.

The Board is pleased to announce that the Company has received the formal approval from the China Securities Regulatory Commission (the “ CSRC ”) (Zheng Jian Xu Ke [2021] No. 1951) (《關 於核准上海君實生物醫藥科技股份有限公司發行境外上市外資股的批覆》 (證監許可[2021] 1951 號)) for the issuance of not more than 36,549,300 new H Shares, all being ordinary shares with par value of RMB1.00 each. The Company will proceed with the issuance of new H Shares in accordance with the relevant laws and regulations and the CSRC’s approval. The Company will fulfill its obligations of information disclosure in respect of the progress of the issuance of new H Shares in a timely manner if and when necessary.

The issuance of new H Shares is still subject to the approval from The Stock Exchange of Hong Kong Limited.

1

Shareholders and potential investors of the Company should note that there is no assurance that the Company will proceed with the issuance of new H Shares, and are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board Shanghai Junshi Biosciences Co., Ltd.* Mr. Xiong Jun Chairman

Shanghai, the PRC, 9 June 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing and Dr. Yao Sheng as executive Directors; Dr. Wu Hai, Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive Directors; and Dr. Chen Lieping, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Jiang Hualiang and Dr. Roy Steven Herbst as independent non-executive Directors.

• For identification purpose only

2